STAAR Reports 6 Percent Increase in Net Sales in Q1-2017

May 12, 2017: By Jon Swedien

STAARSTAAR Surgical had net sales of $20.4 million in Q1-2017, a 6 percent increase over its Q1-2016 net sales, the company reported May 3.

Net sales of STAAR’s Visian Implantable Collamer Lens (ICL) were up 16 percent for Q1-2017 compared with the same quarter in 2016, according to the Monrovia, California, company.

The number of ICLs units sold was up 20 percent for Q1-2017 compared with Q1-2016.

STAAR’s sales for ICLs grew 65 percent in Canada, 65 percent in Japan, and 45 percent in China in Q1-2017 compared with Q1-2016, the company said.

The company’s IOL sales were down 9 percent in Q1-2017 compared with Q1-2016, while the number of units sold was flat. Injector parts dropped 54 percent.

STAAR said it anticipates flat to declining growth for IOL sales in 2017 with the discontinuation of its US silicone IOL business.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022